STOCK TITAN

Algernon Pharmaceuticals Inc - AGNPF STOCK NEWS

Welcome to our dedicated news page for Algernon Pharmaceuticals (Ticker: AGNPF), a resource for investors and traders seeking the latest updates and insights on Algernon Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Algernon Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Algernon Pharmaceuticals's position in the market.

Rhea-AI Summary
Algernon NeuroScience, a subsidiary of Algernon Pharmaceuticals Inc., in collaboration with the Centre for Human Drug Research, will present Phase 1 stroke clinical data on DMT at the Interdisciplinary Conference on Psychedelic Research. The study focused on the safety, tolerability, and pharmacokinetics of sub-psychedelic doses of DMT administered intravenously over 6 hours, showing promising results and paving the way for a Phase 2a trial in acute ischemic stroke patients in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
-
Rhea-AI Summary
Algernon Pharmaceuticals Inc. announces a special CEO interview and Q&A session discussing the recent Ifendprodil transaction with Seyltx and plans for the DMT stroke research program. The event will be hosted by Market Radius Research on April 16th, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.97%
Tags
none
-
Rhea-AI Summary
Algernon Pharmaceuticals Inc. announces plans to advance its intravenous formulation of AP-188 stroke research program after selling its Ifenprodil program for $2M cash and a 20% equity stake in Seyltx. The company established AGN Neuro, a subsidiary, to focus on DMT stroke research, becoming the first to investigate DMT for stroke treatment. Algernon plans to conduct a Phase 2a DMT Stroke study, based on positive Phase 1 trial results, focusing on safety and efficacy measures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.34%
Tags
none
Rhea-AI Summary
Algernon Pharmaceuticals Inc. announces the acquisition of NP-120 research program for chronic cough treatment, Ifenprodil, by Seyltx Inc. The agreement involves a cash payment of USD $2M and a 20% equity stake in Seyltx. Ifenprodil targets the NMDA receptor, specifically GluN2B subunit, to suppress cough reflex. Seyltx plans a Phase 2b study in 2024. Algernon's Phase 2a study data showed significant reduction in cough counts, leading to the decision to advance to Phase 2b.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.81%
Tags
-
Rhea-AI Summary
Algernon Pharmaceuticals Inc. receives a notice of intention to grant a patent from the Chinese Patent Office for its antifibrotic drug candidate NP-251 (Repirinast) for use in the prophylaxis or treatment of renal fibrosis or kidney disease. The patent will be valid through 2038, complementing multiple other patents issued in major world markets. The company also grants restricted share units and stock options to executives, directors, and a consultant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.06%
Tags
none
-
Rhea-AI Summary
Algernon Pharmaceuticals Inc. (AGN) Receives Notice of Allowance from Japanese Patent Office for Treating Idiopathic Pulmonary Fibrosis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) closes non-brokered private placement, raising $280,000 for working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26%
Tags
none
-
Rhea-AI Summary
Algernon Pharmaceuticals Inc. (AGN) announces an increase to its non-brokered private placement, from gross proceeds of $150,000 to $280,000, with each Unit consisting of one Common Share and one Common Share purchase warrant. The Offering is expected to close on December 27, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) announces a non-brokered private placement for gross proceeds of $150,000 through the issuance of units at an issue price of $0.075 per Unit. Each Unit consists of one Class A common share and one Common Share purchase warrant. The Offering is expected to close on December 20, 2023, and the Company will use the proceeds for working capital purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
none
Rhea-AI Summary
Algernon Pharmaceuticals Inc. (AGN) receives a notice of intention to grant from the Chinese Patent Office for patent application No. 112654357, entitled 'Compositions and Methods for Treating Non-Alcoholic Steatohepatitis' with NP-251 (Repirinast). The patent will be valid through 2038, with additional protection possibilities. Repirinast has shown promising results in reducing hepatic fibrosis and NAFLD score in NASH models, positioning it as a strong candidate for both NASH and CKD indications. The company is strategically protecting its compounds through a comprehensive global intellectual property strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.32%
Tags
none
Algernon Pharmaceuticals Inc

OTC:AGNPF

AGNPF Rankings

AGNPF Stock Data

1.57M
14.89M
1.64%
13.88%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Vancouver